Envista (NYSE:NVST) Given New $27.00 Price Target at Mizuho

Envista (NYSE:NVST) had its price objective increased by Mizuho from $24.00 to $27.00 in a research report report published on Tuesday,Benzinga reports. The brokerage currently has a neutral rating on the stock.

A number of other equities analysts have also weighed in on the company. Leerink Partners set a $35.00 target price on Envista and gave the stock an “outperform” rating in a research report on Friday. Zacks Research upgraded shares of Envista from a “hold” rating to a “strong-buy” rating in a report on Friday, February 6th. Piper Sandler reiterated a “neutral” rating and set a $25.00 price objective (up from $21.00) on shares of Envista in a report on Friday. Morgan Stanley set a $19.00 target price on shares of Envista in a research report on Friday. Finally, Barclays started coverage on shares of Envista in a report on Monday, December 8th. They issued an “overweight” rating and a $24.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Envista presently has an average rating of “Moderate Buy” and a consensus price target of $26.71.

Envista Price Performance

Shares of NYSE NVST opened at $30.14 on Tuesday. The firm has a market capitalization of $4.96 billion, a P/E ratio of 107.64, a P/E/G ratio of 2.01 and a beta of 1.01. The firm’s 50-day moving average price is $23.17 and its 200-day moving average price is $21.37. The company has a current ratio of 2.38, a quick ratio of 2.04 and a debt-to-equity ratio of 0.47. Envista has a 1-year low of $14.22 and a 1-year high of $30.36.

Envista (NYSE:NVST) last issued its earnings results on Thursday, February 5th. The company reported $0.38 EPS for the quarter, beating analysts’ consensus estimates of $0.32 by $0.06. The business had revenue of $750.60 million during the quarter, compared to analyst estimates of $680.26 million. Envista had a return on equity of 6.54% and a net margin of 1.73%.The firm’s revenue was up 15.0% compared to the same quarter last year. During the same period in the previous year, the company posted $0.24 EPS. Envista has set its FY 2026 guidance at 1.350-1.450 EPS. Equities research analysts anticipate that Envista will post 1 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Envista

Several institutional investors and hedge funds have recently added to or reduced their stakes in NVST. Farther Finance Advisors LLC boosted its stake in shares of Envista by 317.6% in the 3rd quarter. Farther Finance Advisors LLC now owns 1,349 shares of the company’s stock worth $27,000 after buying an additional 1,026 shares during the last quarter. Caitong International Asset Management Co. Ltd lifted its holdings in Envista by 16,711.1% during the third quarter. Caitong International Asset Management Co. Ltd now owns 1,513 shares of the company’s stock worth $31,000 after acquiring an additional 1,504 shares during the period. Allworth Financial LP boosted its position in Envista by 75.4% in the fourth quarter. Allworth Financial LP now owns 1,805 shares of the company’s stock worth $39,000 after purchasing an additional 776 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Envista by 73.1% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 2,248 shares of the company’s stock valued at $44,000 after purchasing an additional 949 shares during the period. Finally, IFP Advisors Inc increased its position in shares of Envista by 102.9% during the 4th quarter. IFP Advisors Inc now owns 2,112 shares of the company’s stock valued at $46,000 after purchasing an additional 1,071 shares during the last quarter.

Envista News Summary

Here are the key news stories impacting Envista this week:

• Positive Sentiment: Zacks upgraded Envista to a Strong Buy (Zacks Rank #1), which tends to attract momentum/seeking flows into the name. Envista (NVST) Upgraded to Strong Buy
• Positive Sentiment: Zacks also highlights surging earnings-estimate revisions for Envista, signaling analysts expect continued upside to profit forecasts — a direct fundamental driver for the rally. Surging Earnings Estimates Signal Upside for Envista
• Positive Sentiment: Short interest dropped ~23.3% in January to ~8.09M shares (about 5.0% of float and a 3.1 days-to-cover ratio). Fewer shorts reduces one source of downward pressure and can support further upside if momentum continues.
• Positive Sentiment: Market coverage and momentum pieces note Envista at or near a 52‑week high, which can attract trend-following and institutional flows. Envista Gains Renewed Focus As NYSE Composite Tracks Healthcare Names
• Neutral Sentiment: American Banking News reported a modest upward adjustment to Envista’s price target to $26 — a positive sign but not a large re-rating on its own. Envista Price Target Raised to $26
• Neutral Sentiment: Leerink Partners reportedly upgraded Envista (details in the write-up), which adds institutional credibility but the market impact depends on the specifics of the case. Envista Upgraded at Leerink Partners
• Negative Sentiment: Mizuho raised its price target from $24 to $27 but maintained a “neutral” rating — that target sits below recent market levels, implying limited upside from that house and a potential cap on momentum. Mizuho Raises PT to $27, Keeps Neutral

Envista Company Profile

Envista Holdings Corporation is a global dental products company that develops, manufactures and markets a broad portfolio of dental consumables, equipment and technology solutions. Headquartered in Brea, California, Envista serves dental practitioners, specialists and laboratories in more than 150 countries. The company’s offerings span implant, orthodontic, endodontic and restorative product lines as well as digital imaging systems and practice management software.

Envista’s product brands include Nobel Biocare for dental implants and restorative solutions, Ormco for orthodontic appliances and treatment systems, Kerr for restorative and endodontic materials, KaVo for dental imaging and handpieces, and Vista for surgical drills and instruments.